DATASET 2026-08-0941 PROGRAMS INDEXEDTIRZEPATIDE ALL-IN $215–$597/MOEVERY FIGURE CAPTURE-DATED & SOURCE-LINKED
TopGLP1Providers.comverified price index
VERIFIED 2026-08-09

503B bulks list

The list of substances outsourcing facilities may compound from bulk ingredients. The FDA’s April 30, 2026 proposed rule would strike semaglutide, tirzepatide, and liraglutide from it — effectively ending 503B production of these molecules if finalized; the comment period closed June 29, 2026 with the final rule pending.

Updated 2026-08-10 · figures captured 2026-08-09 · how we verify

Seen against the live index: with verified all-in prices spanning $215 to $597 for tirzepatide and $133 to $348 for semaglutide as of 2026-08-09, terms like this one are not pedantry — they are the difference between the advertised number and the billed one. Every definition in this glossary links back to the places in the database and the methodology where the concept does its work.

If the pending rule finalizes as proposed, the 503B half of this market’s supply ends — the largest single risk any prepaid commitment here carries. Related figures live on the pages this term links to, and every one of them regenerates from the same dataset this definition does.

See the term in action across the price database and the methodology.

All-in priceMaintenance-dose basisDose-flat pricingDose-tiered pricingMembership feePrepaid term